The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Copper takes part in redox chemistry, and the same property that makes it useful in enzymes can generate reactive oxygen species when the ion is loosely bound. GHK chelates copper through imidazole, amino, and amide nitrogen donors, which reduces the amount of free copper in solution. Whether that chelation is protective, neutral, or harmful in a given tissue is not settled. Laboratory assays report both antioxidant and pro-oxidant behavior, depending on the conditions and the readout used.
Published work on GHK-Cu is dominated by in vitro experiments and small animal studies. Human trials tend to be short and small, with endpoints such as skin appearance rather than clinical outcomes. Review articles often summarize the same underlying laboratory findings, which can make the evidence base look broader than it is. Several basic questions remain open: the concentration of the intact complex in human tissue, the route by which it crosses the skin barrier, and whether effects seen in culture produce measurable changes in people.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
| Property | Value | Notes |
|---|---|---|
| Copper binding sites | Imidazole, amino, and amide nitrogens | Form chelate rings with Cu(II) |
| Conditional binding constant | Reported near 10^16 at neutral pH | Value depends on method and medium |
| Visible absorption | Broad band in the blue-violet region | Source of the characteristic color |
| Common analytical methods | LC-MS, HPLC, UV-Vis, ICP-OES | Used for identity and copper content |
| Main degradation routes | Oxidation, photolysis, hydrolysis | Accelerated by light, heat, and pH extremes |
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
=== Alan Billis === In 2010, a team led by forensic archaeologist Stephen Buckley mummified Alan Billis using techniques based on 19 years of research of 18th-dynasty Egyptian mummification. The process was filmed for television, for the documentary Mummifying Alan: Egypt's Last Secret. Billis made the decision to allow his body to be mummified after being diagnosed with terminal cancer in 2009. His body currently resides at London's Gordon Museum.
==== MeSH D08.811.600 – multienzyme complexes ==== MeSH D08.811.600.075 – anthranilate phosphoribosyltransferase MeSH D08.811.600.085 – anthranilate synthase MeSH D08.811.600.116 – aspartate carbamoyltransferase MeSH D08.811.600.130 – aspartokinase homoserine dehydrogenase MeSH D08.811.600.200 – cholesterol side-chain cleavage enzyme MeSH D08.811.600.250 – electron transport chain complex proteins MeSH D08.811.600.250.500 – electron-transferring flavoproteins MeSH D08.811.600.250.500.500 – electron transport complex i MeSH D08.811.600.250.500.750 – electron transport complex ii MeSH D08.811.600.250.500.750.500 – succinate dehydrogenase MeSH D08.811.600.250.687 – electron transport complex iv MeSH D08.811.600.250.875 – succinate cytochrome c oxidoreductase MeSH D08.811.600.250.875.249 – electron transport complex ii MeSH D08.811.600.250.875.249.500 – succinate dehydrogenase MeSH D08.811.600.250.875.500 – electron transport complex iii MeSH D08.811.600.317 – fatty acid synthetase complex MeSH D08.811.600.391 – glycine decarboxylase complex MeSH D08.811.600.391.100 – aminomethyltransferase MeSH D08.811.600.391.150 – dihydrolipoamide dehydrogenase MeSH D08.811.600.391.175 – glycine decarboxylase complex h-protein MeSH D08.811.600.391.200 – glycine dehydrogenase (decarboxylating) MeSH D08.811.600.465 – ketoglutarate dehydrogenase complex MeSH D08.811.600.465.500 – dihydrolipoamide dehydrogenase MeSH D08.811.600.541 – lactose synthase MeSH D08.811.600.700 – phosphoenolpyruvate sugar phosphotransferase system MeSH D08.811.600.710 – photosynthetic reaction center complex proteins MeSH D08.811.600.710.249 – light-harvesting protein complexes MeSH D08.811.600.710.374 – cytochrome b6f complex MeSH D08.811.600.710.374.500 – cytochromes b6 MeSH D08.811.600.710.374.750 – cytochromes f MeSH D08.811.600.710.374.875 – plastoquinol-plastocyanin reductase MeSH D08.811.600.710.500 – photosystem i protein complex MeSH D08.811.600.710.750 – photosystem ii protein complex MeSH D08.811.600.715 – polyketide synthases MeSH D08.811.600.720 – prostaglandin-endoperoxide synthases MeSH D08.811.600.720.500 – cyclooxygenase 1 MeSH D08.811.600.720.750 – cyclooxygenase 2 MeSH D08.811.600.730 – proteasome endopeptidase complex MeSH D08.811.600.741 – pyruvate dehydrogenase complex MeSH D08.811.600.741.525 – dihydrolipoamide dehydrogenase MeSH D08.811.600.741.625 – dihydrolipoyllysine-residue acetyltransferase MeSH D08.811.600.741.725 – pyruvate dehydrogenase (lipoamide) MeSH D08.811.600.850 – sucrase-isomaltase complex MeSH D08.811.600.896 – tryptophan synthase
== Similar approaches == The idea of using protein design to accomplish the same goals as DNA origami has surfaced as well. Researchers at the National Institute of Chemistry in Slovenia are working on using rational design of protein folding to create structures much like those seen with DNA origami. The main focus of current research in protein folding design is in the drug delivery field, using antibodies attached to proteins as a way to create a targeted vehicle.
In April 2009, Kardashian and her sister Kourtney announced that they were contracted to star in a spin-off that would follow their move to launch a D-A-S-H store in Miami, Florida. The series, Kourtney and Khloé Take Miami, debuted on E! on August 16, 2009. Starting May 29, 2009, Kardashian joined Miami Top 40 Mainstream outlet WHYI for a weekly four-hour talk/entertainment program, co-hosted by 106 & Park's Terrence J. Khloé and her sisters Kim and Kourtney made a cameo appearance in the Season 3 premiere of the series 90210. Kardashian made an appearance in episodes 2, 4, and 8 of Kourtney and Kim Take New York, which premiered in January 2011. On April 10, 2011, Khloé & Lamar, Kardashian's own show with her then-husband, Lamar Odom, debuted. Kardashian participated in the second season of The Celebrity Apprentice, finishing 10th of 16 candidates by being fired by Donald Trump. It was reported she was fired because of her previous arrest for a DUI. In June 2009, Khloé and her sisters teamed up with the Natural Products Association to create a teeth whitening pen called Idol White. Kardashian appeared in one of PETA's "I'd Rather Go Naked Than Wear Fur" campaigns. The three sisters released a jewelry line in March 2010. In the spring of 2010, the sisters released a clothing line for Bebe. Bebe announced they were dropping the line in December 2010. In September 2010, Kardashian and her sisters released another clothing line, K-Dash on QVC. Kardashian and her sisters marketed a fake tan product, released in 2010 and called Kardashian Glamour Tan.
=== 2020–present === In January 2020, Merck acquired ArQule, developer of ARQ 531, an oral Bruton's tyrosine kinase (BTK) inhibitor, for $2.7 billion. In March 2020, Merck was one of ten companies recognised at the inaugural Manufacturing Awards by New Jersey Business magazine and the New Jersey Business and Industry Association. In June 2020, Merck acquired Themis Bioscience, a company focused on vaccines and immune-modulation therapies for infectious diseases including COVID-19 and cancer. Also in June 2020, Merck Animal Health acquired Quantified Ag, a data and analytics company that monitors cattle body temperature and movement in order to detect illness early. In August 2020, Merck Animal Health acquired IdentiGEN, engaged in DNA-based animal traceability. In September 2020, Merck acquired $1 billion of Seattle Genetics common stock, and agreed to co-develop ladiratuzumab vedotin. In November 2020, Merck announced it would acquire VelosBio for $2.75 billion, developer of VLS-101, an antibody-drug conjugate designed to target Tyrosine kinase-like orphan receptor 1 (ROR1) in both hematological and solid tumors. VLS-101 is currently Phase I and Phase II clinical trials. The company also announced it would acquire OncoImmune for $425 million and its phase 3 candidate, CD24Fc, used in the treatment of patients with severe and critical COVID-19. In February 2021, Merck Animal Health acquired PrognostiX Poultry. In April 2021, Merck acquired Pandion Therapeutics for $1.85 billion, expanding its offering in treating autoimmune diseases. In June 2021, the U.S.
Sources: en.wikipedia.org
=== Analogues === Although several related compounds are disclosed in the original patent, no activity data are provided and it was unclear whether these share tianeptine's unique pharmacological effects. More recent structure-activity relationship studies have since been conducted, providing some further insight on μ-opioid, δ-opioid, and pharmacokinetic activity. Derivatives where the aromatic chlorine substituent is replaced by bromine, iodine or methylthio, and/or the heptanoic acid tail is varied in length or replaced with other groups such as 3-methoxypropyl, show similar or increased opioid receptor activity relative to tianeptine, with up to 13x higher potency than tianeptine itself. Amineptine, the most closely related drug to have been widely studied, is a dopamine reuptake inhibitor with no significant effect on serotonin levels, nor opioid agonist activity. Tianeptinaline and tianeptinostat, analogues of tianeptine, are potent histone deacetylase (HDAC) inhibitors.
In humans, replication protein A is the best-understood member of this family and is used in processes where the double helix is separated, including DNA replication, recombination, and DNA repair. These binding proteins seem to stabilize single-stranded DNA and protect it from forming stem-loops or being degraded by nucleases.
In 1988, after prompting from the United States Congress, the National Institute of General Medical Sciences (National Institutes of Health) (NIGMS) instituted a funding mechanism for biotechnology training. Universities nationwide compete for these funds to establish Biotechnology Training Programs (BTPs). Each successful application is generally funded for five years then must be competitively renewed. Graduate students in turn compete for acceptance into a BTP; if accepted, then stipend, tuition and health insurance support are provided for two or three years during the course of their PhD thesis work. Nineteen institutions offer NIGMS supported BTPs. Biotechnology training is also offered at undergraduate level and in community colleges.
== Physical properties of porous silicon == Physical parameters describing PS are pore diameter, pore density and thickness of the porous layer. During formation of porous silicon layer by means of anodization of a Si wafer, these parameter can be controlled by the Si resistivity, HF concentration, current density and etching time. It is possible to create several porous layers with different pore densities and diameters of the pores on the same substrate by etching with different current densities.
Sources: en.wikipedia.org
== Further reading == Brook CG (1999). "Mechanism of puberty". Horm. Res. 51 Suppl 3 (3): 52–4. doi:10.1159/000053162. PMID 10592444. S2CID 33671883. Holmes SJ, Shalet SM (1996). "Role of growth hormone and sex steroids in achieving and maintaining normal bone mass". Horm. Res. 45 (1–2): 86–93. doi:10.1159/000184765. PMID 8742125. Ottolenghi C, Uda M, Crisponi L, Omari S, Cao A, Forabosco A, Schlessinger D (Jan 2007). "Determination and stability of sex". BioEssays. 29 (1): 15–25. doi:10.1002/bies.20515. hdl:11380/611683. PMID 17187356. S2CID 23824870. Couse JF, Korach KS (June 1998). "Exploring the role of sex steroids through studies of receptor deficient mice". J. Mol. Med. 76 (7): 497–511. doi:10.1007/s001090050244. PMID 9660168. S2CID 6470903. McEwen BS (1992). "Steroid hormones: effect on brain development and function". Horm. Res. 37 Suppl 3 (3): 1–10. doi:10.1159/000182393. PMID 1330863. Simons (Aug 2008). "physiological versus pharmacological steroid hormone actions". BioEssays. 30 (8): 744–56. doi:10.1002/bies.20792. PMC 2742386. PMID 18623071. Han, Thang S.; Walker, Brian R.; Arlt, Wiebke; Ross, Richard J. (17 December 2013). "Treatment and health outcomes in adults with congenital adrenal hyperplasia". Nature Reviews Endocrinology. 10 (2): 115–124. doi:10.1038/nrendo.2013.239. PMID 24342885. S2CID 6090764Figure 2: The adrenal steroidogenesis pathway.{{cite journal}}: CS1 maint: postscript (link)
No well-accepted theory explains the significance of circumcision to the Egyptians, but it appears to have been endowed with great honor and importance as a rite of passage, performed in a public ceremony emphasizing the continuation of family generations and fertility. It may have been a mark of distinction for the elite: the Egyptian Book of the Dead describes the sun god Ra as having circumcised himself.
The four substrates of this enzyme are 4-hydroxybenzoic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are hydroquinone, oxidised NAD+, water, and carbon dioxide. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 4-hydroxybenzoate,NAD(P)H:oxygen oxidoreductase (1-hydroxylating, decarboxylating). This enzyme is also called 4-hydroxybenzoate 1-monooxygenase. This enzyme participates in benzoic acid degradation.
As the strictest of vegetarian diets, a vegan diet excludes all animal products, and can be accompanied by the abstention from animal-derived products, such as leather shoes and silk clothes. Vegetarian diets pose some difficulties. For vitamin B12, depending on the presence or absence of eggs and dairy products in the diet or other reliable B12 sources, vegetarians or vegans may incur a nutritional deficiency. Packaged and processed foods may contain minor quantities of animal ingredients. While some vegetarians scrutinize product labels for such ingredients, others do not object to consuming them, or are unaware of their presence.
Both NAD+ and NADH strongly absorb ultraviolet light because of the adenine. For example, peak absorption of NAD+ is at a wavelength of 259 nanometers (nm), with an extinction coefficient of 16,900 M−1cm−1. NADH also absorbs at higher wavelengths, with a second peak in UV absorption at 339 nm with an extinction coefficient of 6,220 M−1cm−1. This difference in the ultraviolet absorption spectra between the oxidized and reduced forms of the coenzymes at higher wavelengths makes it simple to measure the conversion of one to another in enzyme assays – by measuring the amount of UV absorption at 340 nm using a spectrophotometer. NAD+ and NADH also differ in their fluorescence. Freely diffusing NADH in aqueous solution, when excited at the nicotinamide absorbance of ~335 nm (near-UV), fluoresces at 445–460 nm (violet to blue) with a fluorescence lifetime of 0.4 nanoseconds, while NAD+ does not fluoresce. The properties of the fluorescence signal changes when NADH binds to proteins, so these changes can be used to measure dissociation constants, which are useful in the study of enzyme kinetics. These changes in fluorescence are also used to measure changes in the redox state of living cells, through fluorescence microscopy. NADH can be converted to NAD+ in a reaction catalysed by copper, which requires hydrogen peroxide. Thus, the supply of NAD+ in cells requires mitochondrial copper(II).
Sources: en.wikipedia.org
It is not approved as a pharmaceutical in major markets and is used mainly as a cosmetic ingredient and a laboratory reagent. Regulatory status varies by country and by the product category in which it appears. Claims about therapeutic effects should be treated separately from permitted cosmetic labeling.
Reversed-phase high-performance liquid chromatography and mass spectrometry are common for the peptide portion. Copper content is usually determined by inductively coupled plasma techniques or by spectrophotometry. Ultraviolet-visible spectroscopy takes advantage of the visible absorption band of the copper complex.
Light, oxygen, and elevated temperature promote degradation of the peptide, and strongly acidic or alkaline conditions accelerate hydrolysis. The copper complex is generally more resistant to oxidation than the free peptide. Storage in a dry, dark, cold environment limits loss over time.
Identification usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. The copper content can be measured separately by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. The combination helps distinguish the intact complex from free peptide or free copper.